echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Global data: the global AIDS treatment market will reach 15.3 billion in 2023

    Global data: the global AIDS treatment market will reach 15.3 billion in 2023

    • Last Update: 2015-09-28
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Source: Xinkangjie 2015-9-25 global data said in the latest report that although the whole AIDS market capacity will not change greatly in the next few years, the AIDS therapy market is expected to change to integrated enzyme inhibitor drugs and single drug According to the report of global data, the market value of human immunodeficiency virus (HIV, HIV) therapy will increase from 14 billion US dollars in 2013 to 15.3 billion US dollars in 2023, with a compound annual growth rate of 0.9% in nine major markets (the United States, France, Germany, Italy, Spain, the United Kingdom, Japan, Brazil and China) Represents a low compound annual growth rate Global data said in a new report that in the next few years, although the market capacity of the whole AIDS market will not change greatly, the AIDS therapy market is expected to change to integrase inhibitor drugs and single drugs This change is particularly evident in the US, where fiscal tightening remains the primary obstacle to growth in other markets Dr Moritz Herrmann, an infectious diseases analyst at global data, said that the growth of the AIDS market will be driven mainly by emerging new drugs For example, single drug with stronger efficacy and improved tolerance has been put on the market, and more and more HIV patients are using antiretroviral drugs to control the disease However, due to the limited knowledge of patients and doctors on HIV, the current diagnosis rate of AIDS is relatively low, which increases the spread of the disease and delays the effective management of the disease Between 2013 and 2023, the patent protection rights of several heavy drugs for AIDS treatment expire, and the growth of AIDS market will be affected to some extent For example, Gillette's Atripla is a combination of three components, i.e efavirenz (Sustiva), emtricitabine (emtriva) and tenofovir diooxilfumarate (Viread) Since 2011, its sales have exceeded 3 billion US dollars in a row and reached a peak of 3.6 billion US dollars in 2013 Atripla's patent rights in the United States expire on May 21, 2013 In addition, Germany, China and Brazil will encourage patients to use cheaper generic drugs, which will also affect the AIDS drug market to some extent However, according to the global data report, integrase inhibitors for AIDS treatment, such as the HIV / abacavir / lamivudine of Viiv healthcare and Quad 2 (elvitegrafir / cobicistat / emtricitabine / tenofoviralafenamide [TAF]) of Gilead, will offset the impact of generic drugs on the market in the next few years Herrmann went on to explain: "although there are some new drugs on the market, the market space for AIDS therapy will still be affected by a series of environmental barriers, such as low awareness of patients, social factors related to AIDS in some countries The lack of access to drugs and high drug prices are always the biggest obstacles to AIDS treatment In order to fully deal with the global AIDS epidemic, we must overcome these obstacles "
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.